Market Overview:
The global cardiomyopathy market is expected to grow at a CAGR of 5.5% from 2018 to 2030. The growth in the market can be attributed to the increasing incidence of cardiomyopathy, rising awareness about cardiomyopathy, and technological advancements in the diagnosis and treatment of cardiomyopathy. The global cardiomyopathy market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into dilated cardiomyopathy, hypertrophic cardiomyopathy, and restrictive cardiomi-ypathy. Dilated car-diomyo-pathy accounted for the largest share of the global car-diomyo-pathy market in 2017 owing to its high prevalence rate across all regions. On t he basis o f applicatio n , th e ma rke t i s segmen ted int o hospitals an d diagnost ic centers an d ambulatory services centers . Hospitals accounte d for a majority share o f th e globa l ca rdio myop athy mar ket i n 2 017 due t o th e availability o f advanced diagnostic an d treatment facilities . However , ambulatory services center s are expec ted t o gro w at a highe r CAGR durin g th e forecast period as they offer patients convenient access to care .
Product Definition:
Cardiomyopathy is a disease of the heart muscle. It can cause the heart to become enlarged, thickened, or rigid. This makes it difficult for the heart to pump blood efficiently. Cardiomyopathy can lead to heart failure and death.
Dilated cardiomyopathy:
Dilated cardiomyopathy (DCM) is a heart muscle disease which causes the walls of the heart to become weak and enlarged. The main symptom associated with this disease is frequent shortness of breath. There are various treatments available for this disorder such as medication, surgery, and devices. This treatment varies according to type and severity of DCM.
Hypertrophic cardiomyopathy:
Hypertrophic cardiomyopathy (HCM) is a disorder of heart muscle that causes an abnormal thickening of the heart wall. The walls of the heart become weak due to excessive pumping and this can lead to arrhythmias, or irregular heartbeat. This condition may not cause any symptoms at all; in some cases it may produce only fatigue, dizziness, shortness in breath and palpitations (fast heartbeat).
Application Insights:
Based on the application, the global cardiomyopathy market is segmented into hospitals and diagnostic centers, ambulatory services centers, and others. The hospital and diagnostic center segment dominated the overall market in 2017 owing to a high prevalence of patients suffering from heart-related diseases requiring treatment or diagnosis. According to data published by WHO in 2018, out of every 1 million people globally; around 800 die due to cardiovascular diseases (CVDs). In addition, according to estimates published by NIDDK in 2016; over 585 thousand Americans aged 65 years or above were hospitalized due to CVDs. Thus a large patient base across various regions results in higher revenue generation for cardiology clinics/centers providing diagnostics & treatment facilities for these patients.
The ambulatory services center segment is expected witness lucrative growth during forecast period owing to rising awareness about preventive measures against heart-related disorders coupled with increasing availability of advanced diagnostics tools at affordable prices thereby driving demand for these devices worldwide.
Regional Analysis:
North America dominated the global market in 2017. The high prevalence of dilated, hypertrophic, and restrictive cardiomyopathy conditions in this region is primarily responsible for the largest share of the overall revenue. Moreover, favorable reimbursement policies for patients suffering from these cardiac disorders are also one of the major factors contributing to their large number in North America. For instance, under Medicare Part B coverage is given to patients suffering from DCM or heart failure due to a cardiomyopathy condition.
Asia Pacific is expected to grow at an exponential rate during the forecast period owing to increasing geriatric population and awareness about early diagnosis & treatment options for various cardiac diseases such as dilated & hypertrophic cardiomyopathy among children.
The key players operating in this industry include Abbott; Amgen Inc.
Growth Factors:
- Increasing incidence of cardiomyopathy due to changing lifestyles and increasing prevalence of risk factors such as obesity, hypertension, and diabetes.
- Growing awareness about the symptoms and diagnosis of cardiomyopathy among patients and healthcare professionals.
- Development of novel therapies for the treatment of cardiomyopathy, including stem cell therapy and gene therapy.
- Expansion of the Cardiovascular Disease (CVD) market due to increasing incidence rates of CVDs such as heart attack and stroke.
Scope Of The Report
Report Attributes
Report Details
Report Title
Cardiomyopathy Market Research Report
By Type
Dilated cardiomyopathy, Hypertrophic cardiomyopathy, Restrictive cardiomyopathy
By Application
Hospitals and diagnostic centers, Ambulatory services centers
By Companies
Array BioPharma, Boston Scientific, Cisbio, Covance, Critical Diagnostics, Mylan, Pfizer, Becton Dickinson, BG Medicine, BioMerieux, Bio-Rad
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
146
Number of Tables & Figures
103
Customization Available
Yes, the report can be customized as per your need.
Global Cardiomyopathy Market Report Segments:
The global Cardiomyopathy market is segmented on the basis of:
Types
Dilated cardiomyopathy, Hypertrophic cardiomyopathy, Restrictive cardiomyopathy
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals and diagnostic centers, Ambulatory services centers
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Array BioPharma
- Boston Scientific
- Cisbio
- Covance
- Critical Diagnostics
- Mylan
- Pfizer
- Becton Dickinson
- BG Medicine
- BioMerieux
- Bio-Rad
Highlights of The Cardiomyopathy Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Dilated cardiomyopathy
- Hypertrophic cardiomyopathy
- Restrictive cardiomyopathy
- By Application:
- Hospitals and diagnostic centers
- Ambulatory services centers
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Cardiomyopathy Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Cardiomyopathy is a condition in which the heart muscle becomes enlarged and weakened. This can lead to difficulty breathing, heart failure, and death.
Some of the major players in the cardiomyopathy market are Array BioPharma, Boston Scientific, Cisbio, Covance, Critical Diagnostics, Mylan, Pfizer, Becton Dickinson, BG Medicine, BioMerieux, Bio-Rad.
The cardiomyopathy market is expected to grow at a compound annual growth rate of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Cardiomyopathy Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Cardiomyopathy Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Cardiomyopathy Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Cardiomyopathy Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Cardiomyopathy Market Size & Forecast, 2020-2028
4.5.1 Cardiomyopathy Market Size and Y-o-Y Growth
4.5.2 Cardiomyopathy Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Dilated cardiomyopathy
5.2.2 Hypertrophic cardiomyopathy
5.2.3 Restrictive cardiomyopathy
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospitals and diagnostic centers
6.2.2 Ambulatory services centers
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Cardiomyopathy Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Cardiomyopathy Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Dilated cardiomyopathy
9.6.2 Hypertrophic cardiomyopathy
9.6.3 Restrictive cardiomyopathy
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospitals and diagnostic centers
9.10.2 Ambulatory services centers
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Dilated cardiomyopathy
10.6.2 Hypertrophic cardiomyopathy
10.6.3 Restrictive cardiomyopathy
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospitals and diagnostic centers
10.10.2 Ambulatory services centers
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Dilated cardiomyopathy
11.6.2 Hypertrophic cardiomyopathy
11.6.3 Restrictive cardiomyopathy
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospitals and diagnostic centers
11.10.2 Ambulatory services centers
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Dilated cardiomyopathy
12.6.2 Hypertrophic cardiomyopathy
12.6.3 Restrictive cardiomyopathy
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospitals and diagnostic centers
12.10.2 Ambulatory services centers
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Dilated cardiomyopathy
13.6.2 Hypertrophic cardiomyopathy
13.6.3 Restrictive cardiomyopathy
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospitals and diagnostic centers
13.10.2 Ambulatory services centers
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Cardiomyopathy Market: Competitive Dashboard
14.2 Global Cardiomyopathy Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Array BioPharma
14.3.2 Boston Scientific
14.3.3 Cisbio
14.3.4 Covance
14.3.5 Critical Diagnostics
14.3.6 Mylan
14.3.7 Pfizer
14.3.8 Becton Dickinson
14.3.9 BG Medicine
14.3.10 BioMerieux
14.3.11 Bio-Rad
